If you are alive today, you most likely know, or have known, someone afflicted with Alzheimer’s disease (AD). The World Health Organization estimates that more than 55 million people have dementia worldwide, with AD accounting for 60 to 70% of all cases. For decades, scientists have tested different hypotheses to find and fix the origins of the disease. Many […]

How can clinical trials be designed to best study therapies for treating long COVID? As progress is made in addressing the COVID-19 pandemic with vaccines and treatment pathways, reports about the long-term effects of the infection are building. Post-acute Sequelae of SARS-CoV-2 (PASC) (i.e., long COVID, long-term COVID, long-haul COVID) is an umbrella term used […]

Athira Pharma has completed enrollment in its ACT-AD Phase 2 trial evaluating the safety and efficacy of ATH-1017 in adults with mild-to-moderate Alzheimer’s disease. “The completion of enrollment in our ACT-AD trial is an important step forward in advancing ATH-1017 as a potential new treatment option for patients suffering from Alzheimer’s and other dementias,” Mark Litton, PhD, Athira […]